{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
city
~48 mi. (Guatel, Guatemala, +45 more cities)
facility
Centro Regional de Sub Especialidades Medicas SA ( Site 0604)
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~48 mi. (Guatel, Guatemala, +105 more cities)
facility
Centro Regional de Sub Especialidades Medicas SA ( Site 3003)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~83 mi. (Salcaj√°, Guatemala, +144 more cities)
facility
Centro Medico Integral de Cancerologia CEMIC ( Site 0701)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type